Dear Editor
Azadbakht et al., recently published an interesting study entitled “Evaluation of antibiotic resistance of Helicobacter pylori bacteria obtained from gastric biopsy samples: A cohort study” in the Journal of Annals of Medicine and Surgery [1].
Antibiotic resistance H. pylori infection is considered as one of the main challenge of treatment failure that cause to chronic persistent infection as well as increase the risk of gastric adenocarcinoma [2]. Thus, mass H. pylori eradication is recommended by American gastroenterology society to decline risk of gastric cancer [3,4]. In the subsequent section, we suggest some constructive points to enrich this study:
-
1
Helicobacter pylori (H. pylori) should be stated with italic font throughout the manuscript.
-
2
Routinely, the Etest (previously known as the Epsilometer test), Agar dilution, as well as molecular test e.g. PCR, PCR-RFLP, sequencing method was reliable methods for detection of antibiotic resistance in H. pylori infection [5]. However, the author was not mentioned; antibiotic resistance in H. pylori strains how was detected in this study? Invalidated methods for H. pylori antibiogram can refuse the validity of the current results as a risk bias.
-
3
There are some unclear terms in methods, for example the sentence “Helicobacter pylori was achieved using cellular characteristics in hot staining”, we have not hot staining for detection of H. pylori infection; do you mean gram-staining?
Taking together, better study design in relevant future investigations are need to validate the present findings as well as provide increased understanding about epidemiology of antibiotic resistance in H. pylori infection in such developing countries.
Ethical approval
Not applicable for this study.
Sources of funding
There is no fund for this manuscript.
Author contribution
Masoud Keikha contribute in conceptional, study design, review of the literatures, writing the draft and revision.
Kiarash Ghazvini contribute in writing the draft and revision.
All authors agree with publish in this journal.
Research registration unique identifying number (UIN)
-
1.
Name of the registry: Not applicable.
-
2.
Unique Identifying number or registration ID: Not applicable.
-
3.
Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable.
Guarantor
Not applicable for this study.
Declaration of competing interest
There is no conflict of interest.
References
- 1.Azadbakht S., Moayyedkazemi A., Azadbakht S., Fard S.A., Soroush S. Evaluation of antibiotic resistance of Helicobacter pylori bacteria obtained from gastric biopsy samples: a cohort study. Ann. Med. Surg. 2022 doi: 10.1016/j.amsu.2022.103824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Sugimoto M., Murata M., Yamaoka Y. Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: meta-analysis. World J. Gastroenterol. 2020;26(15):1820. doi: 10.3748/wjg.v26.i15.1820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Lee Y.C., Chen T.H., Chiu H.M., Shun C.T., Chiang H., Liu T.Y., Wu M.S., Lin J.T., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676–682. doi: 10.1136/gutjnl-2012-302240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Howden C.W., Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Am. J. Gastroenterol. 1998;93(12):2330–2338. doi: 10.1111/j.1572-0241.1998.00684.x. [DOI] [PubMed] [Google Scholar]
- 5.Keikha M., Askari P., Ghazvini K., Karbalaei M. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. J. Global Antimicrob. Resist. 2021;S2213-7165(21):00246–00250. doi: 10.1016/j.jgar.2021.10.019. In press. [DOI] [PubMed] [Google Scholar]